Paolo Tarantino: Measuring Recurrence Rates in HR+/HER2- Breast Cancer
Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared on LinkedIn: “Any improvement in cancer care starts from measuring. In our latest JNCI article, we…
Read the full article2d agoen
You might also wanna read
Anirban Maitra։ KRAS-Targeted Vaccine Feasibility in High-Risk Individuals for Pancreatic Cancer
OncoDaily·2h ago
Sarah Sammons and Paolo Tarantino on the Lack of Efficacy Combining T-DXd With Tucatinib
OncoDaily·6h ago
Ermelinda Damko: HER2×EGFR Click Strategy Explores a New Design for Multispecific ADCs
OncoDaily·9h ago
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer
OncoDaily·10h ago
Immune Receptor Plays Dual Role in Promoting T-cell Exhaustion in Cancer
news.northwestern.edu·12h ago
Abeer Alenazi: Does Gedatolisib Approval Signal a Shift Beyond Biomarker-Driven Therapy?
OncoDaily·13h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.